Identification

Name
Digitoxin
Accession Number
DB01396
Type
Small Molecule
Groups
Approved, Investigational
Description

A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)

Structure
Thumb
Synonyms
  • Crystodigin (tn)
  • Digitoksin
  • Digitoxin
  • Digitoxinum
  • Digitoxoside
External IDs
NSC-7529
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Digitaline Welcker Tab 0.1mgTablet.1 mgOralWelcker Lyster Ltd., Division Of Technilab Inc.1951-12-312001-09-05Canada
International/Other Brands
Crystodigin / Tardigal
Categories
UNII
E90NZP2L9U
CAS number
71-63-6
Weight
Average: 764.9391
Monoisotopic: 764.434692134
Chemical Formula
C41H64O13
InChI Key
WDJUZGPOPHTGOT-XUDUSOBPSA-N
InChI
InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
IUPAC Name
4-[(1S,2S,5S,7R,10R,11S,14R,15R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES

Pharmacology

Indication

For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.

Structured Indications
Not Available
Pharmacodynamics

Digitoxin is a cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). Unlike digoxin (which is eliminated from the body via the kidneys), it is eliminated via the liver, so could be used in patients with poor or erratic kidney function. However, it is now rarely used in current UK medical practice. While there have been several controlled trials which have shown digoxin to be effective in a proportion of patients treated for heart failure, there is not the same strong evidence base for digitoxin, although it is presumed to be similarly effective.

Mechanism of action

Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digitoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

TargetActionsOrganism
ASodium/potassium-transporting ATPase subunit alpha-1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Digitoxin exhibits similar toxic effects to the more-commonly used digoxin, namely: anorexia, nausea, vomiting, diarrhoea, confusion, visual disturbances, and cardiac arrhythmias.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
10-hydroxycamptothecinDigitoxin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Investigational
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideDigitoxin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosoureaDigitoxin may decrease the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.Investigational
2-MethoxyestradiolDigitoxin may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideDigitoxin may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneDigitoxin may decrease the cardiotoxic activities of 3,3'-diindolylmethane.Investigational
3,4-Dihydroxybenzoic AcidDigitoxin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
6-O-benzylguanineDigitoxin may decrease the cardiotoxic activities of 6-O-benzylguanine.Investigational
7-HydroxystaurosporineDigitoxin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental, Investigational
8-azaguanineDigitoxin may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-aminocamptothecinDigitoxin may decrease the cardiotoxic activities of 9-aminocamptothecin.Investigational
AbirateroneDigitoxin may decrease the cardiotoxic activities of Abiraterone.Approved
AcebutololAcebutolol may increase the bradycardic activities of Digitoxin.Approved
AclarubicinDigitoxin may decrease the cardiotoxic activities of Aclarubicin.Investigational
Acridine CarboxamideDigitoxin may decrease the cardiotoxic activities of Acridine Carboxamide.Investigational
ActeosideDigitoxin may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibDigitoxin may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneDigitoxin may decrease the cardiotoxic activities of Afimoxifene.Investigational
AlatrofloxacinDigitoxin may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleDigitoxin may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AlcuroniumAlcuronium may increase the arrhythmogenic activities of Digitoxin.Experimental
AldesleukinDigitoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
AlemtuzumabDigitoxin may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlitretinoinDigitoxin may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
AlprenololAlprenolol may increase the bradycardic activities of Digitoxin.Approved, Withdrawn
AltretamineDigitoxin may decrease the cardiotoxic activities of Altretamine.Approved
AlvocidibDigitoxin may decrease the cardiotoxic activities of Alvocidib.Experimental, Investigational
AmikacinThe serum concentration of Digitoxin can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Amiloride.Approved
AminoglutethimideDigitoxin may decrease the cardiotoxic activities of Aminoglutethimide.Approved, Investigational
Aminolevulinic acidDigitoxin may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Digitoxin can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Digitoxin can be increased when it is combined with Amodiaquine.Approved, Investigational
AmonafideDigitoxin may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin.Approved, Investigational
AmrubicinDigitoxin may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineDigitoxin may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideDigitoxin may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleDigitoxin may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveDigitoxin may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinDigitoxin may decrease the cardiotoxic activities of annamycin.Investigational
AP 12009Digitoxin may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Digitoxin may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneDigitoxin may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Digitoxin can be decreased when it is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Digitoxin can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinThe serum concentration of Digitoxin can be decreased when it is combined with Arbekacin.Approved, Investigational
Arotinoid acidDigitoxin may decrease the cardiotoxic activities of TTNPB.Experimental
ArotinololArotinolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
Arsanilic acidDigitoxin may decrease the cardiotoxic activities of Arsanilic acid.Experimental, Vet Approved
Arsenic trioxideDigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
AsparaginaseDigitoxin may decrease the cardiotoxic activities of Asparaginase.Approved
AtazanavirThe metabolism of Digitoxin can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Digitoxin can be decreased when combined with Atomoxetine.Approved
AtracuriumAtracurium may increase the arrhythmogenic activities of Digitoxin.Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Digitoxin.Approved
AxitinibDigitoxin may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineDigitoxin may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineDigitoxin may decrease the cardiotoxic activities of Azathioprine.Approved
Azelaic AcidDigitoxin may decrease the cardiotoxic activities of Azelaic Acid.Approved
BalsalazideThe serum concentration of Digitoxin can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatDigitoxin may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Digitoxin.Experimental
BekanamycinThe serum concentration of Digitoxin can be decreased when it is combined with Bekanamycin.Experimental
BelinostatDigitoxin may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanDigitoxin may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineDigitoxin may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digitoxin.Approved
BesifloxacinDigitoxin may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Digitoxin.Approved
BevacizumabDigitoxin may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Digitoxin.Approved
BexaroteneDigitoxin may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
BicalutamideDigitoxin may decrease the cardiotoxic activities of Bicalutamide.Approved
BinetrakinDigitoxin may decrease the cardiotoxic activities of Binetrakin.Investigational
BisoprololBisoprolol may increase the bradycardic activities of Digitoxin.Approved
BizelesinDigitoxin may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinDigitoxin may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabDigitoxin may decrease the cardiotoxic activities of Blinatumomab.Approved
BoceprevirThe metabolism of Digitoxin can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the bradycardic activities of Digitoxin.Approved
BortezomibDigitoxin may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosentanThe serum concentration of Digitoxin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibDigitoxin may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinDigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BroxuridineDigitoxin may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Digitoxin may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Digitoxin may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Digitoxin.Investigational
BufuralolBufuralol may increase the bradycardic activities of Digitoxin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin.Approved
BupranololBupranolol may increase the bradycardic activities of Digitoxin.Approved
BusulfanDigitoxin may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineDigitoxin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelDigitoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineDigitoxin may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibDigitoxin may decrease the cardiotoxic activities of Cabozantinib.Approved
CalcidiolCalcidiol may increase the arrhythmogenic activities of Digitoxin.Approved, Nutraceutical
CalcipotriolDigitoxin may decrease the cardiotoxic activities of Calcipotriol.Approved
CalciumCalcium may increase the arrhythmogenic activities of Digitoxin.Approved, Nutraceutical
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium CarbonateCalcium Carbonate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium CitrateCalcium Citrate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Digitoxin.Approved, Vet Approved
Calcium lactateCalcium lactate may increase the arrhythmogenic activities of Digitoxin.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate may increase the arrhythmogenic activities of Digitoxin.Experimental
Calcium laevulateCalcium laevulate may increase the arrhythmogenic activities of Digitoxin.Experimental
Calcium pangamateCalcium pangamate may increase the arrhythmogenic activities of Digitoxin.Experimental
Calcium PhosphateCalcium Phosphate may increase the arrhythmogenic activities of Digitoxin.Approved
CamptothecinDigitoxin may decrease the cardiotoxic activities of Camptothecin.Experimental
CanertinibDigitoxin may decrease the cardiotoxic activities of Canertinib.Investigational
CapecitabineDigitoxin may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Digitoxin can be increased when combined with Carbamazepine.Approved, Investigational
CarbimazoleThe serum concentration of Digitoxin can be increased when it is combined with Carbimazole.Approved, Investigational
CarbomycinThe serum concentration of Digitoxin can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinDigitoxin may decrease the cardiotoxic activities of Carboplatin.Approved
CarboquoneDigitoxin may decrease the cardiotoxic activities of Carboquone.Experimental
CarboxyamidotriazoleDigitoxin may decrease the cardiotoxic activities of Carboxyamidotriazole.Investigational
CarfilzomibDigitoxin may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurDigitoxin may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineDigitoxin may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Digitoxin.Approved
CaseinCasein may increase the arrhythmogenic activities of Digitoxin.Approved
CatumaxomabDigitoxin may decrease the cardiotoxic activities of Catumaxomab.Approved, Investigational
CediranibDigitoxin may decrease the cardiotoxic activities of Cediranib.Investigational
CeliprololCeliprolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
CeritinibThe serum concentration of Digitoxin can be increased when it is combined with Ceritinib.Approved
CetuximabDigitoxin may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilDigitoxin may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Digitoxin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin.Approved, Vet Approved
ChlorotrianiseneDigitoxin may decrease the cardiotoxic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digitoxin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinDigitoxin may decrease the cardiotoxic activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinDigitoxin may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
CisatracuriumCisatracurium may increase the arrhythmogenic activities of Digitoxin.Approved, Experimental
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Digitoxin.Approved
CisplatinDigitoxin may decrease the cardiotoxic activities of Cisplatin.Approved
CladribineDigitoxin may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Digitoxin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Digitoxin can be decreased when combined with Clemastine.Approved
ClofarabineDigitoxin may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin.Approved
CloranololCloranolol may increase the bradycardic activities of Digitoxin.Experimental
ClotrimazoleThe metabolism of Digitoxin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Digitoxin can be decreased when combined with Cobicistat.Approved
ColchicineDigitoxin may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CombretastatinDigitoxin may decrease the cardiotoxic activities of Combretastatin.Investigational
ConivaptanThe serum concentration of Digitoxin can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinDigitoxin may decrease the cardiotoxic activities of Cordycepin.Investigational
Coumermycin A1Digitoxin may decrease the cardiotoxic activities of Coumermycin A1.Experimental
CrenolanibDigitoxin may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibDigitoxin may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminDigitoxin may decrease the cardiotoxic activities of Curcumin.Investigational
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Digitoxin.Experimental
CyclophosphamideDigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Digitoxin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateDigitoxin may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineDigitoxin may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibThe serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib.Approved
DacarbazineDigitoxin may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinDigitoxin may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabDigitoxin may decrease the cardiotoxic activities of Daratumumab.Approved
DarunavirThe metabolism of Digitoxin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Digitoxin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinDigitoxin may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Digitoxin.Approved
DecitabineDigitoxin may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Digitoxin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Digitoxin can be decreased when combined with Delavirdine.Approved
DemecolcineDigitoxin may decrease the cardiotoxic activities of Demecolcine.Experimental
Denileukin diftitoxDigitoxin may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinDigitoxin may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DexamethasoneDigitoxin may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneDigitoxin may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolDigitoxin may decrease the cardiotoxic activities of Dianhydrogalactitol.Investigational
DibekacinThe serum concentration of Digitoxin can be decreased when it is combined with Dibekacin.Experimental
DidoxDigitoxin may decrease the cardiotoxic activities of Didox.Investigational
DienogestDigitoxin may decrease the cardiotoxic activities of Dienogest.Approved
diethylnorspermineDigitoxin may decrease the cardiotoxic activities of diethylnorspermine.Investigational
DiethylstilbestrolDigitoxin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved, Investigational
DihydroergotamineThe metabolism of Digitoxin can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinThe serum concentration of Digitoxin can be decreased when it is combined with Dihydrostreptomycin.Investigational, Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Digitoxin.Approved
DiltiazemThe metabolism of Digitoxin can be decreased when combined with Diltiazem.Approved
DinutuximabDigitoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
DocetaxelDigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Dolastatin 10Digitoxin may decrease the cardiotoxic activities of Dolastatin 10.Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Digitoxin.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Digitoxin.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Digitoxin.Approved
DoxifluridineDigitoxin may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinDigitoxin may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Digitoxin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Digitoxin can be decreased when combined with Dronedarone.Approved
DuligotuzumabDigitoxin may decrease the cardiotoxic activities of Duligotuzumab.Investigational
EcabetDigitoxin may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrecolomabDigitoxin may decrease the cardiotoxic activities of Edrecolomab.Experimental, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Digitoxin.Approved
EfaproxiralDigitoxin may decrease the cardiotoxic activities of Efaproxiral.Investigational
EfatutazoneDigitoxin may decrease the cardiotoxic activities of Efatutazone.Investigational
EflornithineDigitoxin may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Digitoxin may decrease the cardiotoxic activities of EG009.Investigational
ElsamitrucinDigitoxin may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EndostatinDigitoxin may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinDigitoxin may decrease the cardiotoxic activities of Enoxacin.Approved, Investigational
EnrofloxacinDigitoxin may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatDigitoxin may decrease the cardiotoxic activities of Entinostat.Investigational
EnzalutamideThe serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the bradycardic activities of Digitoxin.Experimental
Epigallocatechin GallateDigitoxin may decrease the cardiotoxic activities of Epigallocatechin Gallate.Investigational
EpirubicinDigitoxin may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Eplerenone.Approved
EpofolateDigitoxin may decrease the cardiotoxic activities of Epofolate.Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Digitoxin.Approved, Nutraceutical
EribulinDigitoxin may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibDigitoxin may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Digitoxin can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the bradycardic activities of Digitoxin.Approved
EstramustineDigitoxin may decrease the cardiotoxic activities of Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.Approved
EtanidazoleDigitoxin may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilDigitoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateDigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoglucidDigitoxin may decrease the cardiotoxic activities of Etoglucid.Experimental
EtoposideDigitoxin may decrease the cardiotoxic activities of Etoposide.Approved
EverolimusDigitoxin may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanDigitoxin may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneDigitoxin may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindDigitoxin may decrease the cardiotoxic activities of exisulind.Investigational
FenretinideDigitoxin may decrease the cardiotoxic activities of Fenretinide.Investigational
FiacitabineDigitoxin may decrease the cardiotoxic activities of Fiacitabine.Investigational
FleroxacinDigitoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineDigitoxin may decrease the cardiotoxic activities of Floxuridine.Approved
FluconazoleThe metabolism of Digitoxin can be decreased when combined with Fluconazole.Approved
FludarabineDigitoxin may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineDigitoxin may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilDigitoxin may decrease the cardiotoxic activities of Fluorouracil.Approved
FlutamideDigitoxin may decrease the cardiotoxic activities of Flutamide.Approved
FluvoxamineThe metabolism of Digitoxin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneDigitoxin may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinDigitoxin may decrease the cardiotoxic activities of Formycin.Experimental
FosamprenavirThe metabolism of Digitoxin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Digitoxin can be increased when it is combined with Fosaprepitant.Approved
FosbretabulinDigitoxin may decrease the cardiotoxic activities of Fosbretabulin.Investigational
FosphenytoinThe metabolism of Digitoxin can be increased when combined with Fosphenytoin.Approved
FotemustineDigitoxin may decrease the cardiotoxic activities of Fotemustine.Experimental, Investigational
FramycetinThe serum concentration of Digitoxin can be decreased when it is combined with Framycetin.Approved
FulvestrantDigitoxin may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinDigitoxin may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin.Approved, Vet Approved
Fusidic AcidThe serum concentration of Digitoxin can be increased when it is combined with Fusidic Acid.Approved
GallamineGallamine may increase the arrhythmogenic activities of Digitoxin.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Digitoxin.Approved
Gallium nitrateDigitoxin may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinDigitoxin may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinDigitoxin may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibDigitoxin may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinDigitoxin may decrease the cardiotoxic activities of Geldanamycin.Experimental, Investigational
GemcitabineDigitoxin may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinDigitoxin may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinDigitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved
GeneticinThe serum concentration of Digitoxin can be decreased when it is combined with Geneticin.Experimental
GenisteinDigitoxin may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Digitoxin can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Digitoxin can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside CDigitoxin may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GoserelinDigitoxin may decrease the cardiotoxic activities of Goserelin.Approved
GPX-150The serum concentration of Digitoxin can be decreased when it is combined with GPX-150.Investigational
GrepafloxacinDigitoxin may decrease the cardiotoxic activities of Grepafloxacin.Investigational, Withdrawn
GS 0573Digitoxin may decrease the cardiotoxic activities of GS 0573.Investigational
GusperimusDigitoxin may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinDigitoxin may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneDigitoxin may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HexestrolDigitoxin may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin.Approved, Investigational
HydroxychloroquineThe serum concentration of Digitoxin can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateDigitoxin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaDigitoxin may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Digitoxin can be decreased when it is combined with Hygromycin B.Vet Approved
HypericinDigitoxin may decrease the cardiotoxic activities of Hypericin.Investigational
IbrutinibDigitoxin may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinDigitoxin may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibThe serum concentration of Digitoxin can be increased when it is combined with Idelalisib.Approved
IfosfamideDigitoxin may decrease the cardiotoxic activities of Ifosfamide.Approved
ImatinibDigitoxin may decrease the cardiotoxic activities of Imatinib.Approved
ImiquimodDigitoxin may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin.Approved
IndenololIndenolol may increase the bradycardic activities of Digitoxin.Withdrawn
IndinavirThe metabolism of Digitoxin can be decreased when combined with Indinavir.Approved
IndirubinDigitoxin may decrease the cardiotoxic activities of Indirubin.Investigational
Indole-3-carbinolDigitoxin may decrease the cardiotoxic activities of Indole-3-carbinol.Investigational
InfigratinibDigitoxin may decrease the cardiotoxic activities of Infigratinib.Investigational
IniparibDigitoxin may decrease the cardiotoxic activities of Iniparib.Experimental, Investigational
INNO-206The serum concentration of Digitoxin can be decreased when it is combined with INNO-206.Investigational
Interferon beta-1aDigitoxin may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
IobenguaneDigitoxin may decrease the cardiotoxic activities of Iobenguane.Approved, Investigational
IpilimumabDigitoxin may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanDigitoxin may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenDigitoxin may decrease the cardiotoxic activities of Irofulven.Investigational
IrsogladineDigitoxin may decrease the cardiotoxic activities of Irsogladine.Investigational
IsavuconazoniumThe metabolism of Digitoxin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe serum concentration of Digitoxin can be decreased when it is combined with Isepamicin.Experimental
IsosorbideDigitoxin may decrease the cardiotoxic activities of Isosorbide.Approved, Investigational
IsradipineThe metabolism of Digitoxin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Digitoxin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Digitoxin can be increased when it is combined with Ivacaftor.Approved
IxabepiloneDigitoxin may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibDigitoxin may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Digitoxin can be increased when it is combined with Josamycin.Approved, Investigational
KanamycinThe serum concentration of Digitoxin can be decreased when it is combined with Kanamycin.Approved, Investigational, Vet Approved
KaolinThe serum concentration of Digitoxin can be decreased when it is combined with Kaolin.Approved
KetoconazoleThe metabolism of Digitoxin can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Digitoxin can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Digitoxin may decrease the cardiotoxic activities of KOS-1584.Investigational
KRN-7000Digitoxin may decrease the cardiotoxic activities of KRN-7000.Investigational
L-alanosineDigitoxin may decrease the cardiotoxic activities of L-alanosine.Investigational
LabetalolLabetalol may increase the bradycardic activities of Digitoxin.Approved
LandiololLandiolol may increase the bradycardic activities of Digitoxin.Investigational
LanreotideDigitoxin may decrease the cardiotoxic activities of Lanreotide.Approved
LapatinibDigitoxin may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LCL-161Digitoxin may decrease the cardiotoxic activities of LCL-161.Investigational
LeflunomideDigitoxin may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideDigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved
LentinanDigitoxin may decrease the cardiotoxic activities of Lentinan.Experimental, Investigational
LenvatinibDigitoxin may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleDigitoxin may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideDigitoxin may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Digitoxin.Approved
LevofloxacinDigitoxin may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleDigitoxin may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Digitoxin.Approved
LomefloxacinDigitoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved, Investigational
LometrexolDigitoxin may decrease the cardiotoxic activities of Lometrexol.Investigational
LomustineDigitoxin may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineDigitoxin may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
LopinavirThe metabolism of Digitoxin can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Digitoxin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Digitoxin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Digitoxin can be decreased when it is combined with Lumacaftor.Approved
LurtotecanDigitoxin may decrease the cardiotoxic activities of Lurtotecan.Investigational
LycopeneDigitoxin may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideDigitoxin may decrease the cardiotoxic activities of Mafosfamide.Investigational
MannosulfanDigitoxin may decrease the cardiotoxic activities of Mannosulfan.Experimental
MasitinibDigitoxin may decrease the cardiotoxic activities of Masitinib.Investigational, Vet Approved
MasoprocolDigitoxin may decrease the cardiotoxic activities of Masoprocol.Approved, Investigational
MaxacalcitolDigitoxin may decrease the cardiotoxic activities of Maxacalcitol.Approved, Investigational
MebendazoleDigitoxin may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineDigitoxin may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneDigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateDigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateDigitoxin may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanDigitoxin may decrease the cardiotoxic activities of Melphalan.Approved
MepindololMepindolol may increase the bradycardic activities of Digitoxin.Experimental
MequinolDigitoxin may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineDigitoxin may decrease the cardiotoxic activities of Mercaptopurine.Approved
MerestinibDigitoxin may decrease the cardiotoxic activities of Merestinib.Investigational
MesalazineThe serum concentration of Digitoxin can be decreased when it is combined with Mesalazine.Approved
MethimazoleThe serum concentration of Digitoxin can be increased when it is combined with Methimazole.Approved
MethotrexateDigitoxin may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin.Approved
Methyl aminolevulinateDigitoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneDigitoxin may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethylselenocysteineDigitoxin may decrease the cardiotoxic activities of Methylselenocysteine.Investigational
MethyltestosteroneDigitoxin may decrease the cardiotoxic activities of Methyltestosterone.Approved
MethylthiouracilThe serum concentration of Digitoxin can be increased when it is combined with Methylthiouracil.Experimental
MetipranololMetipranolol may increase the bradycardic activities of Digitoxin.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Digitoxin.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Digitoxin.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin.Approved
MetoprineDigitoxin may decrease the cardiotoxic activities of Metoprine.Experimental
MetrizamideThe serum concentration of Digitoxin can be decreased when it is combined with Metrizamide.Approved
MicronomicinThe serum concentration of Digitoxin can be decreased when it is combined with Micronomicin.Experimental
MidodrineDigitoxin may increase the bradycardic activities of Midodrine.Approved
MidostaurinDigitoxin may decrease the cardiotoxic activities of Midostaurin.Approved
MifepristoneThe serum concentration of Digitoxin can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineDigitoxin may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleDigitoxin may decrease the cardiotoxic activities of Misonidazole.Investigational
MitobronitolDigitoxin may decrease the cardiotoxic activities of Mitobronitol.Experimental
MitoguazoneDigitoxin may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolDigitoxin may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinDigitoxin may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneThe serum concentration of Digitoxin can be decreased when it is combined with Mitotane.Approved
MitoxantroneDigitoxin may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Digitoxin.Approved
MizoribineDigitoxin may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Digitoxin may decrease the cardiotoxic activities of MLN576.Investigational
MolgramostimDigitoxin may decrease the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumDigitoxin may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinDigitoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidDigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadifloxacinDigitoxin may decrease the cardiotoxic activities of Nadifloxacin.Investigational
NadololNadolol may increase the bradycardic activities of Digitoxin.Approved
Nalidixic AcidDigitoxin may decrease the cardiotoxic activities of Nalidixic Acid.Approved, Investigational
NamitecanDigitoxin may decrease the cardiotoxic activities of Namitecan.Investigational
NavitoclaxDigitoxin may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Digitoxin can be decreased when it is combined with Neamine.Experimental
NebularineDigitoxin may decrease the cardiotoxic activities of Nebularine.Experimental
NecitumumabDigitoxin may decrease the cardiotoxic activities of Necitumumab.Approved
NedaplatinDigitoxin may decrease the cardiotoxic activities of Nedaplatin.Approved, Investigational
NefazodoneThe metabolism of Digitoxin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineDigitoxin may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Digitoxin can be decreased when combined with Nelfinavir.Approved
NeomycinThe serum concentration of Digitoxin can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Digitoxin.Investigational
NetilmicinThe serum concentration of Digitoxin can be decreased when it is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Digitoxin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Digitoxin can be increased when combined with Nevirapine.Approved
NiguldipineDigitoxin may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibDigitoxin may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideDigitoxin may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineDigitoxin may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibDigitoxin may decrease the cardiotoxic activities of Nintedanib.Approved
NiraparibDigitoxin may decrease the cardiotoxic activities of Niraparib.Approved, Investigational
NivolumabDigitoxin may decrease the cardiotoxic activities of Nivolumab.Approved
nocodazoleDigitoxin may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedDigitoxin may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinDigitoxin may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabDigitoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
OblimersenDigitoxin may decrease the cardiotoxic activities of Oblimersen.Experimental, Investigational
OBP-801Digitoxin may decrease the cardiotoxic activities of OBP-801.Investigational
OctreotideDigitoxin may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabDigitoxin may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinDigitoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
OglufanideDigitoxin may decrease the cardiotoxic activities of Oglufanide.Investigational
OlaparibDigitoxin may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Digitoxin can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Digitoxin can be decreased when it is combined with Olsalazine.Approved
OltiprazDigitoxin may decrease the cardiotoxic activities of Oltipraz.Investigational
Omacetaxine mepesuccinateDigitoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OnapristoneDigitoxin may decrease the cardiotoxic activities of Onapristone.Investigational
OprelvekinDigitoxin may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Digitoxin can be increased when it is combined with Osimertinib.Approved
OxaliplatinDigitoxin may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
Oxolinic acidDigitoxin may decrease the cardiotoxic activities of Oxolinic acid.Experimental
OxprenololOxprenolol may increase the bradycardic activities of Digitoxin.Approved
PaclitaxelDigitoxin may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
Paclitaxel poliglumexDigitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.Experimental, Investigational
PalbociclibThe serum concentration of Digitoxin can be increased when it is combined with Palbociclib.Approved
PalifosfamideDigitoxin may decrease the cardiotoxic activities of Palifosfamide.Investigational
PamidronateDigitoxin may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Digitoxin.Approved
PanitumumabDigitoxin may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatDigitoxin may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digitoxin.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
ParomomycinThe serum concentration of Digitoxin can be decreased when it is combined with Paromomycin.Approved, Investigational
PatupiloneDigitoxin may decrease the cardiotoxic activities of Patupilone.Experimental, Investigational
PazopanibDigitoxin may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinDigitoxin may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinDigitoxin may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseDigitoxin may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabDigitoxin may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedDigitoxin may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
PenclomedineDigitoxin may decrease the cardiotoxic activities of Penclomedine.Investigational
PentobarbitalThe metabolism of Digitoxin can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinDigitoxin may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PertuzumabDigitoxin may decrease the cardiotoxic activities of Pertuzumab.Approved
Phenethyl IsothiocyanateDigitoxin may decrease the cardiotoxic activities of Phenethyl Isothiocyanate.Investigational
PhenobarbitalThe metabolism of Digitoxin can be increased when combined with Phenobarbital.Approved
Phenylacetic acidDigitoxin may decrease the cardiotoxic activities of Phenylacetic acid.Approved
Phenylbutyric acidDigitoxin may decrease the cardiotoxic activities of Phenylbutyric acid.Approved, Investigational
PhenytoinThe metabolism of Digitoxin can be increased when combined with Phenytoin.Approved, Vet Approved
PindololPindolol may increase the bradycardic activities of Digitoxin.Approved
PinometostatDigitoxin may decrease the cardiotoxic activities of Pinometostat.Investigational
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Digitoxin.Approved
PipobromanDigitoxin may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinDigitoxin may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Digitoxin.Experimental
PirfenidoneDigitoxin may decrease the cardiotoxic activities of Pirfenidone.Approved, Investigational
PirlindoleDigitoxin may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneDigitoxin may decrease the cardiotoxic activities of Pixantrone.Approved, Investigational
PlazomicinThe serum concentration of Digitoxin can be decreased when it is combined with Plazomicin.Investigational
PlevitrexedDigitoxin may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinDigitoxin may decrease the cardiotoxic activities of Plicamycin.Approved, Investigational, Withdrawn
PodofiloxDigitoxin may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinDigitoxin may decrease the cardiotoxic activities of Podophyllin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Digitoxin.Approved
PomalidomideDigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibDigitoxin may decrease the cardiotoxic activities of Ponatinib.Approved
Porfimer sodiumDigitoxin may decrease the cardiotoxic activities of Porfimer sodium.Approved, Investigational
porfiromycinDigitoxin may decrease the cardiotoxic activities of porfiromycin.Investigational
PosaconazoleThe metabolism of Digitoxin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the bradycardic activities of Digitoxin.Approved
PralatrexateDigitoxin may decrease the cardiotoxic activities of Pralatrexate.Approved
PrednimustineDigitoxin may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneDigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneDigitoxin may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Digitoxin can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Digitoxin can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineDigitoxin may decrease the cardiotoxic activities of Procarbazine.Approved
PropafenoneThe serum concentration of Digitoxin can be increased when it is combined with Propafenone.Approved
PropylthiouracilThe serum concentration of Digitoxin can be increased when it is combined with Propylthiouracil.Approved
PrulifloxacinDigitoxin may decrease the cardiotoxic activities of Prulifloxacin.Investigational
PuromycinDigitoxin may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Digitoxin.Approved, Vet Approved
PyrazoloacridineDigitoxin may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
QuinacrineDigitoxin may decrease the cardiotoxic activities of Quinacrine.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Digitoxin.Approved
QuinidineThe serum concentration of Digitoxin can be increased when it is combined with Quinidine.Approved
RabusertibDigitoxin may decrease the cardiotoxic activities of Rabusertib.Investigational
Radium Ra 223 DichlorideDigitoxin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedDigitoxin may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabDigitoxin may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabDigitoxin may decrease the cardiotoxic activities of Ranibizumab.Approved
RanimustineDigitoxin may decrease the cardiotoxic activities of Ranimustine.Experimental
RanolazineThe serum concentration of Digitoxin can be increased when it is combined with Ranolazine.Approved, Investigational
RanpirnaseDigitoxin may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Digitoxin.Withdrawn
RegorafenibDigitoxin may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Digitoxin.Approved, Investigational
ResveratrolDigitoxin may decrease the cardiotoxic activities of Resveratrol.Approved, Experimental, Investigational
Rhodamine 6GDigitoxin may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Digitoxin can be decreased when it is combined with Ribostamycin.Approved, Investigational
RidaforolimusDigitoxin may decrease the cardiotoxic activities of Ridaforolimus.Investigational
RifabutinThe metabolism of Digitoxin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Digitoxin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Digitoxin can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Digitoxin can be decreased when combined with Ritonavir.Approved, Investigational
RituximabDigitoxin may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Digitoxin.Approved
RomidepsinDigitoxin may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RoquinimexDigitoxin may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanDigitoxin may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibDigitoxin may decrease the cardiotoxic activities of Rucaparib.Approved, Investigational
RufloxacinDigitoxin may decrease the cardiotoxic activities of Rufloxacin.Experimental
RuxolitinibDigitoxin may decrease the cardiotoxic activities of Ruxolitinib.Approved
SabarubicinThe serum concentration of Digitoxin can be decreased when it is combined with Sabarubicin.Investigational
SalirasibDigitoxin may decrease the cardiotoxic activities of Salirasib.Investigational
SaquinavirThe metabolism of Digitoxin can be decreased when combined with Saquinavir.Approved, Investigational
SaracatinibDigitoxin may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinDigitoxin may decrease the cardiotoxic activities of Satraplatin.Investigational
SeliciclibDigitoxin may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibDigitoxin may decrease the cardiotoxic activities of Semaxanib.Investigational
SemustineDigitoxin may decrease the cardiotoxic activities of Semustine.Experimental, Investigational
SeocalcitolDigitoxin may decrease the cardiotoxic activities of Seocalcitol.Experimental, Investigational
SildenafilThe metabolism of Digitoxin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Digitoxin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Digitoxin can be increased when it is combined with Simeprevir.Approved
SirolimusDigitoxin may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Digitoxin can be decreased when it is combined with Sisomicin.Investigational
SitafloxacinDigitoxin may decrease the cardiotoxic activities of Sitafloxacin.Experimental, Investigational
SizofiranDigitoxin may decrease the cardiotoxic activities of Sizofiran.Investigational
SoblidotinDigitoxin may decrease the cardiotoxic activities of Soblidotin.Investigational
SolithromycinThe serum concentration of Digitoxin can be increased when it is combined with Solithromycin.Investigational
SonidegibDigitoxin may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SorafenibDigitoxin may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Digitoxin.Approved
SP1049CThe serum concentration of Digitoxin can be decreased when it is combined with SP1049C.Investigational
SparfloxacinDigitoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved, Investigational
Sparfosic acidDigitoxin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinDigitoxin may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Digitoxin can be decreased when it is combined with Spectinomycin.Approved, Investigational, Vet Approved
SpiramycinThe serum concentration of Digitoxin can be increased when it is combined with Spiramycin.Approved
squalamineDigitoxin may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Digitoxin may decrease the cardiotoxic activities of SRT501.Investigational
St. John's WortThe serum concentration of Digitoxin can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Digitoxin can be increased when it is combined with Stiripentol.Approved
StreptomycinThe serum concentration of Digitoxin can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinDigitoxin may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Digitoxin.Approved
SulfisoxazoleThe metabolism of Digitoxin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneDigitoxin may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacDigitoxin may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digitoxin.Approved, Investigational
SunitinibDigitoxin may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminDigitoxin may decrease the cardiotoxic activities of Suramin.Approved, Investigational
TalaporfinDigitoxin may decrease the cardiotoxic activities of Talaporfin.Investigational
TalazoparibDigitoxin may decrease the cardiotoxic activities of Talazoparib.Investigational
TalinololTalinolol may increase the bradycardic activities of Digitoxin.Investigational
TamoxifenDigitoxin may decrease the cardiotoxic activities of Tamoxifen.Approved
TaselisibDigitoxin may decrease the cardiotoxic activities of Taselisib.Investigational
TaurolidineDigitoxin may decrease the cardiotoxic activities of Taurolidine.Investigational
TegafurDigitoxin may decrease the cardiotoxic activities of Tegafur.Approved
TelaprevirThe metabolism of Digitoxin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Digitoxin can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Digitoxin can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinDigitoxin may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinDigitoxin may decrease the cardiotoxic activities of Temoporfin.Approved, Investigational
TemozolomideDigitoxin may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusDigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideDigitoxin may decrease the cardiotoxic activities of Teniposide.Approved
TertatololTertatolol may increase the bradycardic activities of Digitoxin.Experimental
TestolactoneDigitoxin may decrease the cardiotoxic activities of Testolactone.Approved, Investigational
TezacitabineDigitoxin may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideDigitoxin may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaDigitoxin may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinDigitoxin may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiazofurineDigitoxin may decrease the cardiotoxic activities of Tiazofurine.Experimental
TiboloneDigitoxin may decrease the cardiotoxic activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Digitoxin can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the bradycardic activities of Digitoxin.Approved
TioguanineDigitoxin may decrease the cardiotoxic activities of Tioguanine.Approved
Tiomolibdate ionDigitoxin may decrease the cardiotoxic activities of Tiomolibdate ion.Investigational
TipifarnibDigitoxin may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineDigitoxin may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibDigitoxin may decrease the cardiotoxic activities of Tivozanib.Investigational
TobramycinThe serum concentration of Digitoxin can be decreased when it is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Digitoxin can be decreased when it is combined with Tocilizumab.Approved
TolevamerThe risk or severity of adverse effects can be increased when Tolevamer is combined with Digitoxin.Approved
TopotecanDigitoxin may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin.Approved
ToremifeneDigitoxin may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabDigitoxin may decrease the cardiotoxic activities of Tositumomab.Approved, Investigational
TrabectedinDigitoxin may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibDigitoxin may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabDigitoxin may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineDigitoxin may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TrebananibDigitoxin may decrease the cardiotoxic activities of Trebananib.Investigational
TremelimumabDigitoxin may decrease the cardiotoxic activities of Tremelimumab.Investigational
TreosulfanDigitoxin may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarDigitoxin may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinDigitoxin may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene.Approved
TriaziquoneDigitoxin may decrease the cardiotoxic activities of Triaziquone.Experimental
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin.Approved, Vet Approved
TrilostaneDigitoxin may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateDigitoxin may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptolideDigitoxin may decrease the cardiotoxic activities of Triptolide.Investigational
TriptorelinDigitoxin may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideDigitoxin may decrease the cardiotoxic activities of Trofosfamide.Investigational
TrovafloxacinDigitoxin may decrease the cardiotoxic activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxacitabineDigitoxin may decrease the cardiotoxic activities of Troxacitabine.Investigational
TubercidinDigitoxin may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Digitoxin.Approved
TylosinThe serum concentration of Digitoxin can be increased when it is combined with Tylosin.Vet Approved
UbenimexDigitoxin may decrease the cardiotoxic activities of Ubenimex.Experimental, Investigational
Uracil mustardDigitoxin may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanDigitoxin may decrease the cardiotoxic activities of Vadimezan.Investigational
ValrubicinDigitoxin may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibDigitoxin may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideDigitoxin may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Digitoxin.Approved
VeliparibDigitoxin may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibDigitoxin may decrease the cardiotoxic activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Digitoxin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Digitoxin can be decreased when combined with Verapamil.Approved
VerteporfinDigitoxin may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneDigitoxin may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineDigitoxin may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineDigitoxin may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineDigitoxin may decrease the cardiotoxic activities of Vindesine.Approved, Investigational
VinflunineDigitoxin may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineDigitoxin may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideDigitoxin may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibDigitoxin may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin ADigitoxin may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Digitoxin can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatDigitoxin may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
VorozoleDigitoxin may decrease the cardiotoxic activities of Vorozole.Experimental
ZiprasidoneThe metabolism of Digitoxin can be decreased when combined with Ziprasidone.Approved
Zoptarelin doxorubicinThe serum concentration of Digitoxin can be decreased when it is combined with Zoptarelin doxorubicin.Investigational
ZorubicinDigitoxin may decrease the cardiotoxic activities of Zorubicin.Experimental
Zuretinol acetateDigitoxin may decrease the cardiotoxic activities of Zuretinol acetate.Investigational
Food Interactions
  • Avoid avocado.
  • Avoid bran and high fiber foods within 2 hours of taking this medication.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Avoid salt substitutes containing potassium.
  • Limit garlic, ginger, gingko, and horse chestnut.

References

General References
  1. Belz GG, Breithaupt-Grogler K, Osowski U: Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7. [PubMed:11525233]
  2. Kurowski V, Iven H, Djonlagic H: Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies. Intensive Care Med. 1992;18(7):439-42. [PubMed:1469187]
  3. Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P: Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs. 2001 Jun;12(5):475-83. [PubMed:11395576]
  4. Hippius M, Humaid B, Sicker T, Hoffmann A, Gottler M, Hasford J: Adverse drug reaction monitoring--digitoxin overdosage in the elderly. Int J Clin Pharmacol Ther. 2001 Aug;39(8):336-43. [PubMed:11515708]
External Links
Human Metabolome Database
HMDB15468
KEGG Drug
D00297
KEGG Compound
C06955
PubChem Compound
441207
PubChem Substance
46506035
ChemSpider
389987
BindingDB
46356
ChEBI
28544
ChEMBL
CHEMBL254219
Therapeutic Targets Database
DAP000120
PharmGKB
PA449316
Wikipedia
Digitoxin
ATC Codes
C01AA04 — Digitoxin
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCystic Fibrosis (CF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral.1 mg
Prices
Unit descriptionCostUnit
Digitoxin powder486.85USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)255.5 °CPhysProp
water solubility3.9 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.85SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0289 mg/mLALOGPS
logP2.33ALOGPS
logP3.6ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)7.18ChemAxon
pKa (Strongest Basic)0.24ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area182.83 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity191.72 m3·mol-1ChemAxon
Polarizability83.58 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9718
Blood Brain Barrier-0.557
Caco-2 permeable-0.8386
P-glycoprotein substrateSubstrate0.8528
P-glycoprotein inhibitor IInhibitor0.5557
P-glycoprotein inhibitor IINon-inhibitor0.6021
Renal organic cation transporterNon-inhibitor0.8473
CYP450 2C9 substrateNon-substrate0.8687
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.8902
CYP450 2C9 inhibitorNon-inhibitor0.9082
CYP450 2D6 inhibitorNon-inhibitor0.9412
CYP450 2C19 inhibitorNon-inhibitor0.9258
CYP450 3A4 inhibitorNon-inhibitor0.901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9381
Ames testNon AMES toxic0.9233
CarcinogenicityNon-carcinogens0.9637
BiodegradationNot ready biodegradable0.9671
Rat acute toxicity4.4764 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Inhibitor0.7759
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (12.6 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Mass Spectrum (Electron Ionization)MSsplash10-052g-9620000000-5ddc0df4702d2f0b8581
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Cardenolide glycosides and derivatives
Alternative Parents
Steroidal glycosides / Oligosaccharides / 14-hydroxysteroids / O-glycosyl compounds / Oxanes / Butenolides / Tertiary alcohols / Enoate esters / Secondary alcohols / Cyclic alcohols and derivatives
show 7 more
Substituents
Cardanolide-glycoside / Steroidal glycoside / Oligosaccharide / 14-hydroxysteroid / Hydroxysteroid / Glycosyl compound / O-glycosyl compound / 2-furanone / Oxane / Cyclic alcohol
show 19 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
cardenolide glycoside (CHEBI:28544) / cardanolide, Cardanolides and derivatives, Cardanolide and derivatives, Cardiac glycosides (C06955) / Cardanolides and derivatives (LMST01120018)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248]
  2. Marcus FI, Ryan JN, Stafford MG: The reactivity of derivatives of digoxin and digitoxin as measured by the Na-K-atpase displacement assay and by radioimmunoassay. J Lab Clin Med. 1975 Apr;85(4):610-20. [PubMed:123547]
  3. Prignitz R, Frohlich D, Hoffmeister G: [Influence of roentgen rays on electrolyte changes and metabolism of the myocardium. VII. Radiation-induced inhibition of the sodium- and potassium--activated microscomal-trasport ATPase]. Strahlentherapie. 1976 Apr;151(4):356-65. [PubMed:131389]
  4. Bluschke V, Bonn R, Greeff K: Increase in the (Na+ + K+)-ATPase activity in heart muscle after chronic treatment with digitoxin or potassium deficient diet. Eur J Pharmacol. 1976 May;37(1):189-91. [PubMed:132355]
  5. Fricke U: [New aspects on the mode of action of cardiac glycosides]. Fortschr Med. 1976 Nov 11;94(32):1037-45. [PubMed:136410]
  6. Hauck C, Potter T, Bartz M, Wittwer T, Wahlers T, Mehlhorn U, Scheiner-Bobis G, McDonough AA, Bloch W, Schwinger RH, Muller-Ehmsen J: Isoform specificity of cardiac glycosides binding to human Na+,K+-ATPase alpha1beta1, alpha2beta1 and alpha3beta1. Eur J Pharmacol. 2009 Nov 10;622(1-3):7-14. doi: 10.1016/j.ejphar.2009.08.039. Epub 2009 Sep 12. [PubMed:19751721]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name
CYP11A1
Uniprot ID
P05108
Uniprot Name
Cholesterol side-chain cleavage enzyme, mitochondrial
Molecular Weight
60101.87 Da
References
  1. Wang SW, Lin H, Hwang JJ, Wang PS: Inhibition of testosterone secretion by digitoxin in rat testicular interstitial cells. J Cell Biochem. 1999 Jul 1;74(1):74-80. [PubMed:10381263]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Hage DS, Sengupta A: Characterisation of the binding of digitoxin and acetyldigitoxin to human serum albumin by high-performance affinity chromatography. J Chromatogr B Biomed Sci Appl. 1999 Mar 5;724(1):91-100. [PubMed:10202961]
  2. Dasgupta A, Vega AE, Wells A, Datta P: Sensitive methods for determination of free digitoxin concentration using digitoxin immunoassays: demonstration of elevated free digitoxin concentration caused by digitoxin-phenytoin interaction by applying these new techniques. Ther Drug Monit. 1999 Dec;21(6):625-30. [PubMed:10604823]
  3. Datta P, Dasgupta A: Interactions between drugs and Asian medicine: displacement of digitoxin from protein binding site by bufalin, the constituent of Chinese medicines Chan Su and Lu-Shen-Wan. Ther Drug Monit. 2000 Apr;22(2):155-9. [PubMed:10774625]
  4. Dasgupta A, Paul A, Wells A: Uremic sera contain inhibitors that block digitoxin-valproic acid interaction. Am J Med Sci. 2001 Oct;322(4):204-8. [PubMed:11678517]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ...
Gene Name
SLCO4C1
Uniprot ID
Q6ZQN7
Uniprot Name
Solute carrier organic anion transporter family member 4C1
Molecular Weight
78947.525 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Pauli-Magnus C, Murdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF: P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43. [PubMed:11284449]

Drug created on July 08, 2007 11:03 / Updated on November 09, 2017 02:59